News & Updates

Show Multimedia Only
MDT without ADT delays systemic therapy initiation in recurrent prostate cancer

MDT without ADT delays systemic therapy initiation in recurrent prostate cancer

21 Nov 2022 byStephen Padilla

In patients with solitary metastatic recurrences of prostate cancer, metastasis-directed therapy (MDT without androgen deprivation therapy (ADT) can lead to delayed initiation of systemic therapy, according to a study.

21 Nov 2022
Testosterone, prostate volume influence lower urinary tract symptoms in prostate cancer

Testosterone, prostate volume influence lower urinary tract symptoms in prostate cancer

10 Nov 2022

Among prostate cancer patients on androgen deprivation therapy (ADT), a small prostate and higher reductions in testosterone levels appear to aggravate storage symptoms, a recent study has found.

10 Nov 2022